Astex Pharmaceuticals, Inc.

Astex Pharmaceuticals, Inc. (“Astex”), is committed to the fight against cancer. Astex is developing a proprietary pipeline of novel therapies for the treatment of solid tumors and hematological malignancies. These include the novel oral hypomethylating agents decitabine and cedazuridine (ASTX727) and azacitidine and cedazuridine (ASTX030) for the treatment of myelodysplastic syndromes and acute myeloid leukemia; tolinapant (ASTX660) for the treatment of T-Cell lymphomas; the oral ERK1/2 inhibitor ASTX029 and the oral MDM2 inhibitor ASTX295 for the treatment of solid tumors, and the oral LSD-1 inhibitor TAS1440 and the oral RNR inhibitor TAS1553 for the treatment of AML. The company also has multiple partnered products being commercialized and in development under collaborations with leading pharmaceutical companies. Astex is a member of the Otsuka group of pharmaceutical companies. Otsuka is one of Japan’s largest pharmaceutical companies; the group also includes Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd and Taiho Oncology, Inc. Subject to regulatory approvals, Astex’s products will be commercialized in the US and Canada by Taiho subsidiaries, and in the rest of the world by Otsuka subsidiaries. Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of human diseases, and nutraceutical products for the maintenance of everyday health. Astex has its clinical development headquarters located in Pleasanton, CA, USA, and its drug discovery headquarters located in Cambridge, UK. Otsuka’s headquarters is located in Tokyo, Japan. For more information about Astex Pharmaceuticals, Inc. please visit: https://www.astx.com... More Info Less Info